Key Record Dates
| ClinicalTrials.gov Identifier: | NCT01449461 |
|---|---|
| Brief Title: | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) |
| First Submitted : | September 30, 2011 |
| First Submitted that Met QC Criteria : | October 6, 2011 |
| First Posted : | October 10, 2011 (Estimate) |
| Results First Submitted : | May 26, 2017 |
| Results First Submitted that Met QC Criteria : | May 26, 2017 |
| Results First Posted : | June 21, 2017 |
| Last Update Submitted that Met QC Criteria : | July 26, 2021 |
| Last Update Posted : | August 17, 2021 |